Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “Company”) has initiated the Phase I clinical trial of HX111, an independently developed OX40-targeting antibody-drug conjugate candidate for the treatment of relapsed/refractory lymphoma and solid tumors. According to the announcement, the first patient enrollment and dosing have been successfully completed. HX111 binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity. Once internalized via endocytosis, the linker is cleaved by lysosomal proteases to release a potent payload, thereby inducing tumor cell apoptosis.

The announcement emphasizes that OX40 is highly expressed in certain lymphoma and solid tumors, for which there are limited treatment options. HX111 is described as the first OX40-targeted ADC drug worldwide to publicly enter clinical trials, indicating a significant first-mover advantage in an early exploratory field. The announcement also advises caution, noting that HX111 may not ultimately be successfully developed or marketed. Shareholders and potential investors are urged to exercise prudence in any dealings related to the Company’s shares.